Ossdsign AB (Publ) reported revenues for the period October - November 2023. For the period, company reported Preliminary total revenues amount to SEK 25.2 million, mainly attributable to a continued strong market performance of the orthobiologics franchise and some extraordinary orders from a large hospital system. According to preliminary and unaudited data, sales of OssDsign Catalyst amounted to SEK 18.8 million during the period of October - November 2023, whereas OssDsign Cranial recorded sales of SEK 6.4 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.23 SEK | +3.94% | -5.91% | +15.38% |
May. 14 | Transcript : OssDsign AB, Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | OssDsign AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.38% | 80.99M | |
+10.11% | 127B | |
-5.15% | 11.34B | |
+6.07% | 9.11B | |
+37.46% | 5.53B | |
+8.53% | 3.45B | |
-8.69% | 2.87B | |
-6.38% | 2.1B | |
-10.91% | 2.08B | |
-23.21% | 1.78B |
- Stock Market
- Equities
- OSSD Stock
- News OssDsign AB
- Ossdsign AB Reports Revenues for the Period October - November 2023